Development of Special Biological Products
Abstract
Rift Valley Fever (RVF) vaccine production was completed and the vaccine submission for Lots 11 through 20 was forwarded to USAMRIID. The test for adventitious agents in Production Seed Virus (RVF 184 Ba) was completed in L-cells. Two production lots of FRhL-2 and three of MRC-5 were stabilized and frozen this year. Two lots of FRhL-2 and partial lots of MRC-5 were shipped to USAMRIID. The production scheme worked well and five lots of VEE vaccine were prepared. Storage stability of TC-83, VEE vaccine was evaluated this year. Chikungunya strain 168 was passed twice in suckling mice and brain tissue was extracted. The preparation of Rift Valley Fever (RVF) HA antigen with a titer of 1:1024 as requested was completed this year. A total of 77 extractions was made and 15 batches of infected suckling mouse livers harvested. Lot 1-80, 1800 vials, was shipped to USAMRIID.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 1981
- Accession Number
- ADA138678
Entities
People
- C. K. Lee
- D. E. Craig
- G. R. French
- J. L. Demeio
- W. J. Thomas